Page 149 - Haematologica Vol. 109 - July 2024

ARTICLE - Patterns of lower risk MDS progresion
A.G. Jain et al.
alleviating transfusion burden and/or achieving hematologic improvement should be further studied. Identifying those LR MDS patients with higher risk features of disease pro- gression or disease-related death within two years will be crucial to tailor therapy accordingly.
Disclosures
AK reports research support from Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, and Morphosys; consultancy fees from Imago Biosciences, Incyte, Blue- print Medicines Corporation, Novartis, Abbvie, GSK - Sier- ra Oncology, Bristol Myers Squibb, Pharmaessentia, and CTI Biopharma; honoraria from Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Si- erra Oncology, Bristol Myers Squibb, Pharmaessentia, and CTI Biopharma; and has been a member of the Speakers Bureau for Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, and CTI Biopharma. OC has received research funding from Syntrix Pharmaceuticals. KS reports consultancy fees from Pfizer, Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, and Bristol Myers Squibb; has sat on the Advisory Board of Pfiz- er, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, and Bristol Myers Squibb; has received research funding from Pfizer, Syntrix Pharmaceuticals, and Incyte; and honoraria from Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, and Bristol Myers Squibb. JEL has received consultancy fees from Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novar- tis, Agios/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma/Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, and Servier; and research funding from Syntrix
References
1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
2. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
3. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351-1361.
4. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22(3):538-543.
5. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
6. Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North
Pharmaceuticals, and Celgene/ Bristol Myers Squibb. EP has received research funding from Bristol Myers Squibb, Syntrix Pharmaceuticals, Kura, and Incyte; and honoraria from Taiho, Stemline, and Blueprint. DAS has sat on the Ad- visory Board of Intellia, Aprea, Syndax, Bristol Myers Squibb, Nemucore, Agios, AbbVie, Kite, Shattuck Labs, and Novartis; has received consultancy fees from Takeda, Novartis, and Magenta; has sat on the Speakers Bureau of Bristol Myers Squibb and Incyte; has received research funding from Aprea and Syntrix Pharmaceuticals; and Patents & Royalties from Lixte. RK has received consultancy fees from Servier, AbbVie, Geron, Acceleron Pharma, Taiho Oncology, Novartis, Jazz Pharmaceuticals, and Bristol Myers Squibb; honoraria from Servier, AbbVie, CTI BioPharma, Innovent, PharmaEssentia, Takeda, Jazz Pharmaceuticals, and Bristol Myers Squibb; has sat on the Speakers Bureau of Servier, AbbVie, Jazz Pharmaceuticals and Bristol Myers Squibb; has sat on the Advisory Board of CTI BioPharma, Taiho Oncology, Pharma- Essentia, Takeda, Novartis, Bristol Myers Squibb; and has received research funding from Bristol Myers Squibb. AGJ, SB, LA, NAA and DK have no conflicts of interest to disclose.
Contributions
AGJ, SB, and LA analyzed the data. NAA collected the data. AGJ wrote the manuscript. RK conceptualized the retro- spective review and performed a thorough revision of the manuscript. DK, ST, AK, OC, EP, KS, JEL and DAS reviewed the manuscript.
Funding
No funding was received for this work.
Data-sharing agreement
The MDS database related to this study is not available.
Am. 2010;24(2):443-457.
7. Volpe VO, Garcia-Manero G, Komrokji RS. Myelodysplastic
syndromes: a new decade. Clin Lymphoma Myeloma Leuk.
2022;22(1):1-16.
8. de Swart L, Smith A, Johnston TW, et al. Validation of the
revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170(3):372-383.
9. Komrokji R, Ramadan H, Al Ali N, et al. Validation of the Lower- Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015;15 Suppl:S60-63.
10. Kawabata H, Usuki K, Shindo-Ueda M, et al. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Int J Hematol. 2019;110(5):533-542.
11. Angelucci E, Greenberg P, Izquierdo M, Garcia-Manero G. Iron chelation in transfusion-dependent patients with low- to
Haematologica | 109 July 2024
2163